Advertisement

Antiangiogenic therapy: Not just for cancer anymore?

Authors

  • Vijay H. Shah M.D.,

    Corresponding author
    1. Gastrointestinal Research Unit, Mayo Clinic, Rochester, MN
    • Gastrointestinal Research Unit, Mayo Clinic, Rochester, MN
    Search for more papers by this author
  • Jordi Bruix M.D.

    Corresponding author
    1. BCLC Group, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
    • BCLC Group, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
    Search for more papers by this author

  • See Article on Page 1245

  • Potential conflict of interest: Dr. Bruix advises and received grants from Bayer, Lilly, and Novartis. He also advises Schering-Plough and received grants from Pharmexa and EISAI.

No abstract is available for this article.

Ancillary